Becker's Healthcare January 4, 2024
Erica Carbajal

The FDA is looking into whether hair loss, aspiration and suicidal thoughts may be side effects of GLP-1 receptor agonists, a popular class of weight-loss drugs.

The agency on Jan. 2 published a summary of reports received through its Adverse Event Reporting System, or FAERS, saying it is “evaluating the need for regulatory action” after receiving reports of alopecia, aspiration and suicidal thoughts in people using medications such as Ozempic and Wegovy. The reports are based on data collected from July through September.

The FDA’s site notes that the appearance of a drug on the list “means that the FDA has identified a potential safety issue, but it does not mean that the FDA has identified a causal relationship...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Patient / Consumer, Pharma, Pharma / Biotech, Provider
FDA issues flu vaccine recommendations: 5 respiratory updates
5 Digital Health Areas To Be Impacted By The FDA Layoffs
FDA Approves First Biosimilar to Omalizumab
Trump's Nominees to Run FDA, NIH Get Greenlighted by Senate Committee
FDA Debuts a New Communications and Compliance Tool for Device Data Integrity Concerns

Share This Article